Reproxalap for Dry Eye Disease | Aldeyra Therapeutics, Inc.
Reproxalap, a novel small molecule drug, inhibits RASP to reduce ocular inflammation in dry eye disease. Clinical trials show significant activity, with potential for early, broad efficacy and a unique product profile. Studied in over 1,800 patients, it's safe, with mild, transient discomfort reported. Aldeyra plans to advance 0.25% topical ocular reproxalap for treatment.
Reference News
Reproxalap, a novel small molecule drug, inhibits RASP to reduce ocular inflammation in dry eye disease. Clinical trials show significant activity, with potential for early, broad efficacy and a unique product profile. Studied in over 1,800 patients, it's safe, with mild, transient discomfort reported. Aldeyra plans to advance 0.25% topical ocular reproxalap for treatment.